Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 HPV vaccine for cancer and wart prevention.

Literature DB >> 25609521

HPV vaccine for cancer and wart prevention.

Michael R Kolber¹, Adrienne J Lindblad².

Abstract

Entities: Disease

Mesh：

Substances：
Papillomavirus Vaccines

Year: 2015 PMID： 25609521 PMCID： PMC4301765

Source DB: PubMed Journal: Can Fam Physician ISSN： 0008-350X Impact factor: 3.275

× No keyword cloud information.

13 in total

1. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.

Authors: Diane M Harper; Eduardo L Franco; Cosette M Wheeler; Anna-Barbara Moscicki; Barbara Romanowski; Cecilia M Roteli-Martins; David Jenkins; Anne Schuind; Sue Ann Costa Clemens; Gary Dubin
Journal: Lancet Date: 2006-04-15 Impact factor: 79.321

2. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males.

Authors: Anna R Giuliano; Joel M Palefsky; Stephen Goldstone; Edson D Moreira; Mary E Penny; Carlos Aranda; Eftyhia Vardas; Harald Moi; Heiko Jessen; Richard Hillman; Yen-Hwa Chang; Daron Ferris; Danielle Rouleau; Janine Bryan; J Brooke Marshall; Scott Vuocolo; Eliav Barr; David Radley; Richard M Haupt; Dalya Guris
Journal: N Engl J Med Date: 2011-02-03 Impact factor: 91.245

3. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.

Authors:
Journal: N Engl J Med Date: 2007-05-10 Impact factor: 91.245

4. Adverse events following immunization in Ontario's female school-based HPV program.

Authors: Tara Harris; Dawn M Williams; Jill Fediurek; Tsui Scott; Shelley L Deeks
Journal: Vaccine Date: 2014-01-15 Impact factor: 3.641

5. Epidemiologic classification of human papillomavirus types associated with cervical cancer.

Authors: Nubia Muñoz; F Xavier Bosch; Silvia de Sanjosé; Rolando Herrero; Xavier Castellsagué; Keerti V Shah; Peter J F Snijders; Chris J L M Meijer
Journal: N Engl J Med Date: 2003-02-06 Impact factor: 91.245

6. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.

Authors: Joakim Dillner; Susanne K Kjaer; Cosette M Wheeler; Kristján Sigurdsson; Ole-Erik Iversen; Mauricio Hernandez-Avila; Gonzalo Perez; Darron R Brown; Laura A Koutsky; Eng Hseon Tay; Patricia García; Kevin A Ault; Suzanne M Garland; Sepp Leodolter; Sven-Eric Olsson; Grace W K Tang; Daron G Ferris; Jorma Paavonen; Matti Lehtinen; Marc Steben; F Xavier Bosch; Elmar A Joura; Slawomir Majewski; Nubia Muñoz; Evan R Myers; Luisa L Villa; Frank J Taddeo; Christine Roberts; Amha Tadesse; Janine T Bryan; Roger Maansson; Shuang Lu; Scott Vuocolo; Teresa M Hesley; Eliav Barr; Richard Haupt
Journal: BMJ Date: 2010-07-20

7. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.

Authors: Suzanne M Garland; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Diane M Harper; Sepp Leodolter; Grace W K Tang; Daron G Ferris; Marc Steben; Janine Bryan; Frank J Taddeo; Radha Railkar; Mark T Esser; Heather L Sings; Micki Nelson; John Boslego; Carlos Sattler; Eliav Barr; Laura A Koutsky
Journal: N Engl J Med Date: 2007-05-10 Impact factor: 91.245

HPV vaccine for cancer and wart prevention.

1. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.

2. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males.

3. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.

4. Adverse events following immunization in Ontario's female school-based HPV program.

5. Epidemiologic classification of human papillomavirus types associated with cervical cancer.

6. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.

7. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.

8. Anaphylaxis following quadrivalent human papillomavirus vaccination.

9. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine.

10. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students.

Review 1. Mechanistic and Technical Challenges in Studying the Human Microbiome and Cancer Epidemiology.